[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myasthenia-gravis-ocular\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myasthenia-gravis-ocular":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100612134","phase-3-a-study-of-telitacicept-in-patients-with-ocular-myasthenia-gravis-omg-100612134",false,"NCT07249632","A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)","A Phase III Trial of Telitacicept in Patients With Ocular Myasthenia Gravis","Inclusion Criteria:\n\n1. Voluntarily signed the informed consent form.\n2. Age 12 to 80 years, inclusive, male or female.\n3. Body weight ≥30 kg.\n4. Diagnosis of Myasthenia Gravis (MG) with documented clinical features consistent with the disease.\n5. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Type I.\n6. On a stable standard-of-care (SOC) treatment regimen.\n\nExclusion Criteria:\n\n1. Concomitant autoimmune diseases requiring systemic corticosteroid therapy.\n2. Clinically significant laboratory abnormalities.\n3. Use of other immunosuppressants (not part of the stable SOC) within 1 month prior to randomization.\n4. Presence of an acute or chronic infection requiring treatment.\n5. Current active hepatitis or history of severe liver disease.\n6. Positive for HIV antibodies.\n7. Positive for syphilis antibodies (non-specific or specific).\n8. Poorly controlled diabetes mellitus, defined as HbA1c \\>9.0% or fasting blood glucose ≥11.1 mmol\u002FL.\n9. Subjects with thymoma (classified as ≤ Stage II for benign and ≥ Stage III for malignant according to the Masaoka staging system) .\n10. Presence of uncontrolled chronic degenerative diseases, psychiatric disorders, or neurological diseases other than MG that could interfere with study assessments.\n11. Other diseases causing ptosis, peripheral muscle weakness, or diplopia (e.g., Graves' ophthalmopathy, blepharospasm, progressive external ophthalmoplegia, muscular dystrophy, brainstem or cranial nerve lesions, etc.).\n12. Known allergy to human-derived biological products.","ALL","12 Years","80 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible subjects aged 12 to 80 years with a diagnosis of OMG (Myasthenia Gravis Foundation of America \\[MGFA\\] Clinical Classification Type I) will be randomized in a 1:1 ratio to receive either Telitacicept or a matching placebo. Subjects must be on a stable standard-of-care therapy and have an MG Impairment Index (PRO) ocular score of ≥6 at screening and baseline.The dose is age and weight based.The primary objective is to evaluate the efficacy of Telitacicept compared to placebo in treating OMG.The primary efficacy endpoint is the change from baseline in the MGII (PRO) ocular score at Week 24. Secondary endpoints include changes from baseline in other ocular and total scores from MGII, Myasthenia Gravis-Activities of Daily Living (MG-ADL), MG Clinical Absolute Score, and the 15-item Myasthenia Gravis Quality of Life Revised scale (MG-QOL15r). Safety and tolerability will be monitored throughout the study.",[27],"Myasthenia Gravis, Ocular","RECRUITING","2026-04-03",{"date":31,"type":32},"2026-04-09","ACTUAL",{"date":34,"type":32},"2026-01-13",{"date":36,"type":21},"2027-02-28",{"name":38,"class":39},"RemeGen Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":67,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":40},"100563559","myasthenia-gravis-foundation-of-america-global-mg-patient-registry-100563559","NCT06617741","Myasthenia Gravis Foundation of America Global MG Patient Registry","MGFAPR","Inclusion Criteria:\n\n* age over 18\n* positive MG diagnosis\n\nExclusion Criteria:\n\n* age under 18\n* misdiagnosed with MG","18 Years",{"count":50,"type":21},3800,"15 Years","OBSERVATIONAL","The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States. The main questions it aims to answer are:\n\n* How and when are people with MG diagnosed?\n* What are the most common symptoms associated with MG?\n* What treatments are being used to treat MG?\n* What are the impacts of MG on activities of daily living, employment and quality of life?\n* What are the experiences with exacerbation, hospitalization and healthcare access for people with MG? Participants will answer a survey to enroll in the study, and be invited to fill out an update survey twice a year.",[55,56,57,58,59,60,61,62,63,27,64,65,66],"Myasthaenia Gravis","Myasthenia","Myasthenia Gravis Associated with Thymoma","Myasthenia Gravis Crisis","Myasthenia Gravis Exacerbations","Myasthenia Gravis Generalised","Myasthenia Gravis with Exacerbation (Disorder)","Myasthenia Gravis, Adult Form","Myasthenia Gravis, Generalized","Myasthenia Gravis, Thymectomy","Myasthenia Gravis","Myasthenia Gravis, MuSK",[68,69,70,71,72],"myasthenia","patient registry","MGFA","Myasthenia Gravis Foundation of America","myasthenia gravis","2024-09-26",{"date":75,"type":32},"2024-09-27",{"date":77,"type":32},"2013-10-12",{"date":79,"type":21},"2029-09-19",{"name":71,"class":81},"OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":91,"conditions":92,"keywords":100,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":40},"100455749","predictors-and-prognostic-factors-of-myasthenia-gravis-outcome-100455749","NCT05214612","Predictors and Prognostic Factors of Myasthenia Gravis Outcome","Inclusion Criteria:\n\n1. Age from 16 years and older.\n2. Gender: both sexes are included.\n3. Clinical Diagnosis of MG with supporting evidence as:\n\n   1. unequivocal clinical response to pyridostigmine\n   2. decrement \\>10% in repetitive nerve stimulations study (RNS).\n4. Willingness to sample collection, imaging study and other disease-related examinations and assessments.\n\nExclusion Criteria:\n\n1. Age younger than 16 years.\n2. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.\n3. Severe systemic illness affecting life-expectancy.","16 Years",{"count":90,"type":21},30,"This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG.\n\nThis information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.",[65,93,94,95,96,97,63,27,58,98,62,99],"Autoimmune Diseases of the Nervous System","Neuromuscular Junction Diseases","Thymoma","Thymus Hyperplasia","Nervous System Diseases","Myasthenia Gravis With Exacerbation (Disorder)","Myasthenia Gravis, Juvenile Form",[101,102,65,103],"Predictors","Prognostic factors","Outcome","2024-07-30",{"date":106,"type":32},"2024-07-31",{"date":108,"type":32},"2022-01-01",{"date":110,"type":21},"2025-03-31",{"name":112,"class":81},"Assiut University"]